About
About Oncolys BioPharma Inc
Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer. The company also develops OBP-601(Censavudine), which is in phase II clinical trial to treat progressive supranuclear palsy, amyotrophic lateral sclerosis, and aicardi-goutieres syndrome; OBP-702, which is in preclinical trial to treat pancreatic cancer; OBP-201, which is in preclinical trial to treat viral infections; OBP-702 for the treatment of ophthalmology which is in preclinical trial. In addition, it develops TelomeScan (OBP-401 and OBP-1101), which is in pilot study trial to treat cancer testing. The company was incorporated in 2004 and is headquartered in Minato, Japan.
Visit company website
5 years, 6 months ago
Oncolys BioPharma Inc is currently in a long term downtrend where the price is trading 6.1% below its 200 day moving average.
From a valuation standpoint, the stock is 20.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 56.1.
Oncolys BioPharma Inc's total revenue sank by 83.9% to $107M since the same quarter in the previous year.
Its net income has dropped by 70.9% to $-550M since the same quarter in the previous year.
Based on the above factors, Oncolys BioPharma Inc gets an overall score of 1/5.